Atlas Venture Life Science Advisors

Investment decisions are guided by the general partners of Atlas Venture, including Jean-François Formela, Bruce Booth, and Jason Rhodes, who have decades of experience in life sciences venture capital (per Atlas Venture website). The advisory team works alongside these partners to deploy capital into early-stage biotech opportunities.

The advisors access proprietary deal flow through Atlas Venture's direct venture capital activities, which include sourcing from academic institutions, scientific conferences, and the firm's network of entrepreneurs-in-residence. Atlas Venture has a history of incubating companies internally, providing the advisors with early access to novel therapeutic platforms (per the firm).

The advisors participate primarily in early-stage investments, including Series A rounds and pre-clinical/clinical-stage opportunities. They may also engage in select follow-on financings in later rounds for existing portfolio companies. The focus remains on company formation and initial institutional rounds.

Atlas Venture Life Science Advisors is not a family office. It operates as an asset manager or registered investment advisory entity affiliated with Atlas Venture, which is a venture capital firm. The advisors serve institutional and high-net-worth clients seeking exposure to life sciences venture capital.

The firm concentrates on therapeutics, including small molecules, biologics, gene editing, and cell therapies. Atlas Venture has backed companies in oncology, rare diseases, immunology, and central nervous system disorders (per public company disclosures). Medical devices and diagnostics have historically been less central to their strategy.